SCHEMBL20190119

SCHEMBL20190119

NC(CCC(=O)Nc1ccc2ccccc2c1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 11/20 0.70
CYP1A2 P05177 2/20 0.65
SLC1A3 P43003 1/20 0.61
SLC1A2 P43004 1/20 0.61
SLC1A1 P43005 1/20 0.61
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
MAPT P10636 2/20 0.57
POLB P06746 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
RAB9A P51151 3/20 0.57
SMN1; SMN2 Q16637 2/20 0.57
NPC1 O15118 2/20 0.57
LMNA P02545 1/20 0.57
GAA P10253 1/20 0.56
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP2C19 P33261 1/20 0.55
HIF1A Q16665 1/20 0.55
HDAC1 Q13547 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29687817 1.00 LTA4H (0.70) LTA4HCYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL10908490 1.00 LTA4H (0.70) LTA4HCYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL30074475 0.86 CYP1A2 (0.62) LTA4HCYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL19859923 0.86 SLC1A3 (0.80) LTA4HCYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL2522620 0.84 LTA4H (0.91) LTA4HSLC1A3SLC1A2SLC1A1MAPT
SCHEMBL176813 0.84 LTA4H (0.91) LTA4HSLC1A3SLC1A2SLC1A1MAPT
SCHEMBL20238889 0.82 LTA4H (1.00) LTA4HSLC1A3SLC1A2SLC1A1MAPT
SCHEMBL20238887 0.82 LTA4H (1.00) LTA4HSLC1A3SLC1A2SLC1A1MAPT
SCHEMBL29395053 0.81 LTA4H (0.62) LTA4HCYP1A2SLC1A3SLC1A2SLC1A1
SCHEMBL3096584 0.81 CYP1A2 (0.73) CYP1A2MEN1KMT2AMAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240101509-A1 NON-PEPTIDIC CELL-PENETRATING MOTIFS OHIO STATE INNOVATION FOUNDATION 2024-03-28 US claimed
US-20240033318-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION 2024-02-01 US claimed
US-11814341-B2 Non-peptidic cell-penetrating motifs OHIO STATE INNOVATION FOUNDATION (US) 2023-11-14 US claimed
US-20230212235-A1 LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-06 US claimed
WO-2021138397-A1 LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES OHIO STATE INNOVATION FOUNDATION (US) 2021-07-08 WO claimed
US-20260098262-A9 COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHY ENTRADA THERAPEUTICS INC (US) 2026-04-09 US disclosed
US-20260070948-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO OHIO STATE INNOVATION FOUNDATION (US) 2026-03-12 US disclosed
US-20260070947-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-03-12 US disclosed
EP-4706689-A2 COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS Entrada Therapeutics, Inc. (US) 2026-03-11 EP disclosed
US-20260028630-A1 HYBRID OLIGONUCLEOTIDES ENTRADA THERAPEUTICS INC (US) 2026-01-29 US disclosed
US-20260008813-A1 CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-01-08 US disclosed
US-20260008812-A1 CELL-PENETRATING PEPTIDE COMPOUNDS OHIO STATE INNOVATION FOUNDATION (US) 2026-01-08 US disclosed
WO-2019148195-A2 CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN OHIO STATE INNOVATION FOUNDATION (US) 2019-08-01 WO disclosed
WO-2019148194-A2 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION (US) 2019-08-01 WO disclosed
WO-2019148194-A2 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION OHIO STATE INNOVATION FOUNDATION (US) 2019-08-01 WO disclosed
WO-2019148195-A2 CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN OHIO STATE INNOVATION FOUNDATION (US) 2019-08-01 WO disclosed
WO-2019070962-A1 BICYCLIC PEPTIDYL INHIBITORS OHIO STATE INNOVATION FOUNDATION (US) 2019-04-11 WO disclosed
WO-2019070962-A1 BICYCLIC PEPTIDYL INHIBITORS OHIO STATE INNOVATION FOUNDATION (US) 2019-04-11 WO disclosed
WO-2018098231-A1 CELL-PENETRATING PEPTIDE SEQUENCES OHIO STATE INNOVATION FOUNDATION (US) 2018-05-31 WO disclosed
WO-2018098231-A1 CELL-PENETRATING PEPTIDE SEQUENCES OHIO STATE INNOVATION FOUNDATION (US) 2018-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028630-A1 HYBRID OLIGONUCLEOTIDES RNGTT, BCDIN3D, RNMT LTA4H 4328/4885CYP1A2 4866/4885SLC1A3 935/4885
US-20240101509-A1 NON-PEPTIDIC CELL-PENETRATING MOTIFS TIMM50, TIMM10, PITRM1 LTA4H 3859/4885CYP1A2 4766/4885SLC1A3 757/4885
US-20260008812-A1 CELL-PENETRATING PEPTIDE COMPOUNDS SLC38A7, SLC7A1, SLC6A7 LTA4H 3540/4885CYP1A2 4033/4885SLC1A3 20/4885
US-20230212235-A1 LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES LNPEP, SPPL2B, CNBP LTA4H 4316/4885CYP1A2 4885/4885SLC1A3 508/4885
US-20260098262-A9 COMPOUNDS AND METHODS FOR SKIPPING EXON 44 IN DUCHENNE MUSCULAR DYSTROPHY UTRN, SMN1; SMN2, UPF1 LTA4H 3638/4885CYP1A2 4811/4885SLC1A3 30/4885
US-20260070947-A1 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS SLC7A1, SLC38A7, SLC6A19 LTA4H 4237/4885CYP1A2 4771/4885SLC1A3 22/4885
US-11814341-B2 Non-peptidic cell-penetrating motifs TIMM50, TIMM10, PITRM1 LTA4H 3859/4885CYP1A2 4766/4885SLC1A3 757/4885
US-20260070948-A1 CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO SLC7A1, SLC38A7, SLC6A19 LTA4H 3988/4885CYP1A2 4695/4885SLC1A3 11/4885
US-20260008813-A1 CELL-PENETRATING PEPTIDE COMPOUNDS SLC7A1, SLC38A7, SLC6A19 LTA4H 3896/4885CYP1A2 4565/4885SLC1A3 11/4885
US-20240033318-A1 PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION CHP1, NFATC1, PPP3R1 LTA4H 4052/4885CYP1A2 4838/4885SLC1A3 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.